X0609 4 2026-05-11 1 0001645666 Kezar Life Sciences, Inc. KZR 0001608578 Garner Elizabeth false C/O KEZAR LIFE SCIENCES, INC. 4000 SHORELINE COURT, SUITE 300 SOUTH SAN FRANCISCO CA 94080 true false false false 0 Stock Option (right to buy) 26.40 2026-05-11 4 D 0 3500 0 D 2033-06-14 Common Stock 3500 0 D Stock Option (right to buy) 6.70 2026-05-11 4 D 0 5000 0 D 2034-06-19 Common Stock 5000 0 D Stock Option (right to buy) 4.46 2026-05-11 4 D 0 5000 0 D 2035-06-17 Common Stock 5000 0 D Stock Option (right to buy) 22.80 2026-05-11 4 D 0 1779 0 D 2029-12-17 Common Stock 1779 0 D Stock Option (right to buy) 22.80 2026-05-11 4 D 0 889 0 D 2030-06-23 Common Stock 889 0 D Stock Option (right to buy) 22.80 2026-05-11 4 D 0 2600 0 D 2031-06-27 Common Stock 2600 0 D Stock Option (right to buy) 22.80 2026-05-11 4 D 0 2600 0 D 2032-06-15 Common Stock 2600 0 D Pursuant to the terms of the Agreement and Plan of Merger, dated as of March 30, 2026 (the "Merger Agreement"), each option to acquire shares of Issuer common stock (the "Company Stock Options") that had a per share exercise price equal to or greater than $6.955 per share ("Cash Amount") (an "Out-of-the-Money Option"), was automatically cancelled and ceased to exist after completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer (the "Merger"), effective as of May 11, 2026, with the Issuer continuing as the surviving entity and a wholly owned subsidiary of Parent (the "Effective Time") , and no consideration was delivered in exchange for such Out-of-the-Money Option. Pursuant to the terms of the Merger Agreement, each Company Stock Option that had a per share exercise price less than the Cash Amount (an "In-the-Money Option") was automatically cancelled and converted at the Effective Time into the right to receive (A) an amount in cash, without interest, equal to the product obtained by multiplying (x) the excess of the Cash Amount over the exercise price per share underlying such Company Stock Option at the Effective Time by (y) the number of shares underlying such In-the-Money Option, subject to the terms and conditions specified in the Merger Agreement and (B) one CVR in respect of each share underlying such In-the-Money Option. /s/ Marc Belsky, Attorney-in-Fact 2026-05-11